ACAD three-lens brief
Evidence-based stock research on ACAD. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA below 200-day MA (death-cross regime); price below both. · Underperforming SPY by 8.5pp over 30 days.
- 50-day MA below 200-day MA (death-cross regime); price below both.
- Underperforming SPY by 8.5pp over 30 days.
- P/E of 8.7 — trading at a value multiple.
- Analyst mean target $30.53 — 66% above current (19 analysts).
- Reported earnings on 2026-11-04.
ACAD closed at $18.37 (+0.49%) as of 2026-11-12. Market cap: $3.17B. P/E (trailing) 8.7. Price is below the 50-day MA and below the 200-day MA. Positives: p/E of 8.7 — trading at a value multiple.; analyst mean target $30.53 — 66% above current (19 analysts).. Concerns: 50-day MA below 200-day MA (death-cross regime); price below both.; underperforming SPY by 8.5pp over 30 days.. Last quarter: Revenue $342.29M, net income $53.52M, free cash flow $46.27M.
Why three lenses on ACAD, not one.
A single reasoning model has blind spots it doesn’t know about. We examine ACAD across Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://www.clearpathinvest.app/embed/ACAD" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath ACAD brief"></iframe>